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There are few nonhuman primate models of enhanced HIV susceptibility. Such models can improve
comprehension of HIV acquisition risk factors and provide rigorous testing platforms for preclinical prevention
strategies. This paper reviews past, current, and proposed research on macaque HIV acquisition risk models and
identifies areas where modeling is significantly lacking. We compare different experimental approaches and provide
practical considerations for designing macaque susceptibility studies. Modifiable (mucosal and systemic coinfections,
hormonal contraception, and rectal lubricants) and non-modifiable (hormonal fluctuations) risk factors are highlighted.
Risk acquisition models via vaginal, rectal, and penile challenge routes are discussed. There is no consensus on the best
statistical model for evaluating increased susceptibility, and additional research is required. The use of enhanced
susceptibility macaque models would benefit multiple facets of the HIV research field, including basic acquisition
and pathogenesis studies as well as the vaccine and other biomedical preventions pipeline.
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The use of nonhuman primates has proven to be a crit-
ical component of modeling and understanding mecha-
nisms of HIV acquisition as well as testing biomedical
interventions to prevent infection (reviewed in [1–5]).
Macaque models have helped to describe mechanics of
mucosal virus acquisition [2, 6, 7] and provide know-
ledge used to formulate effective prevention strategies.
However, most macaque models of HIV acquisition used
to develop and test biomedical HIV preventions utilize
carefully controlled study arms and do not incorporate
confounding experimental factors that could alter sus-
ceptibility, or infection risk. It is important to under-
stand and consider these susceptibility-altering factors.
A multitude of epidemiologic studies have highlighted
coinfections, pre-existing conditions, certain behaviors,
exogenous hormone use, and other factors widely found
in at-risk human populations that are known or suspected
to increase HIV infection risk [8–16]. In attempts to refine
preclinical testing models, one could model susceptibility
enhancement. Candidate preventions could then be evalu-
ated with these models to ask whether the intervention is* Correspondence: ekersh@cdc.gov
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bility and still prevent infection. However, macaque
models of enhanced susceptibility models are few, and the
number of models which could then be used to rigorously
test biomedical interventions in such “real-world” con-
texts, and possibly better inform preclinical evaluations of
HIV preventions, is also limited. Moreover, such models
would have useful applications apart from prevention test-
ing, including evaluation of suspected harmful products
(e.g., those hypothesized to increase HIV acquisition risk
based on epidemiologic observations, in vitro testing, etc.).
Potentially, the use of animal models of increased suscep-
tibility could be used to prevent failures in large-scale hu-
man clinical trials. There have been instances, particularly
in HIV vaccine research, in which susceptibility to infec-
tion is unintentionally increased (e.g., HVTN 505, STEP
Trial; [17, 18]). Thus, another benefit of an appropriate
risk model could be to serve as an additional “gate keeper”
of the safety of pre-clinical intervention candidates prior
to advancement to clinical trials.
The paucity of risk models in macaques is a testament
to the complex process of their development and study
design validation. Our group has explored several ex-
perimental approaches for macaque models of enhanced
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and provide strategic considerations for designing ma-
caque susceptibility models. Focusing primarily on modifi-
able risk factors (as opposed to internal host factors), this
review discusses nonhuman primate models of enhanced
HIV susceptibility using SIV (simian immunodeficiency
virus) or SHIV (simian-HIV, chimeric virus of SIV ex-
pressing HIV envelope proteins), while highlighting their
scarcity and the developmental difficulties. This review is
organized such that reported findings and nonhuman pri-
mate models are discussed in the context of the studies’
analytical and/or design approaches. For each approach,
we review the various susceptibility factors studied,
models, and scientific findings and then highlight areas on
which future studies might build upon and contribute to
that model system of enhancement or increased infection
risk or susceptibility (e.g., the ability to observe increased
infections in experimental animals versus controls).
Study design and statistical analysis approaches for
susceptibility studies using nonhuman primate models
The design of a susceptibility or risk enhancement study
to date has generally followed one of three approaches,
or perhaps even a combination thereof: repeated expo-
sures, analyzed by a log-rank test; dose titration compari-
son, commonly analyzed by a form of logistic regression;
or presence/absence of infection (following exposure to
the proposed enhancement factor), commonly analyzed by
a probability statistic, such as a chi-square or Fisher’s exact
test (Fig. 1). There does not seem to be a specific or best-
suited strategy for any given type or group of susceptibility
enhancement factors. For example, as will be further
discussed below, modeling of risk enhancement with a
coinfection (e.g., malaria, schistosomiasis, HSV-2,
Chlamydia trachomatis, Trichomonas vaginalis) can be
achieved with any of the three aforementioned analyt-
ical approaches [19–23].
Repeated low-dose exposures
With the repeated exposures approach, a Kaplan-Meier
plot (Fig. 1a) is usually constructed with the number of
exposures along the x-axis, or, with naturally cycling fe-
male pigtail macaques [23], the number of menstrual cy-
cles during exposures. Increased susceptibility is inferred
by a significant left-shifted survival curve of the experi-
mental arm (indicated by the dotted line in Fig. 1a), rela-
tive to the control curve. Using this approach, we
recently described a pigtail macaque model of SHIV ac-
quisition risk enhancement due to sexually transmitted
infection (STI) coinfection with Chlamydia trachomatis
and Trichomonas vaginalis [23] (Table 1). The suscepti-
bility study compared infection rates between nine STI-
positive and seven control macaques receiving repeated
low-dose SHIVSF162p3 exposures. Because of the varyingnatural susceptibility during the menstrual cycle (pigtail
macaques have lunar cycles, similar to humans) [24, 25],
infections were analyzed by completed menstrual cycles
(one menstrual cycle deemed equivalent to one SHIV
susceptibility period) [23]. SHIV susceptibility was en-
hanced in STI-positive macaques (p = 0.04, log-rank),
with a 2.5 times as high relative risk of infection, com-
pared to controls (95 % CI 1.1, 5.6) [23]. A contributing
factor to this enhancement is likely the increased levels
of inflammatory mucosal cytokines observed during the
STI inoculation and SHIV challenge phases [23].
With a repeated low-dose exposure susceptibility
model, it is important to acknowledge the difficulty in
determining the appropriate low virus dose when devel-
oping these models, and it is critical to identify the opti-
mal virus dose that leaves sufficient numbers of control
animals uninfected after repeated challenges. Depending
on the extent of virus stock characterization (and con-
sidering also the route of challenge), determining this
ideal challenge dose may require many macaques for
virus titration studies prior to a susceptibility study.
Dose variation
Another option would be to compare virus dose titra-
tions between experimental groups (e.g., with and with-
out hypothesized enhancement factor; Fig. 1b). Using
this study design, animals are first challenged with very
dilute virus, and, after confirming the absence of infec-
tion, challenges continue in similar fashion with increas-
ing concentrations of virus until an animal is infected. A
benefit to this design is that, after resting, uninfected an-
imals can be re-enrolled. However, a potential problem
is that upon re-challenge of exposed animals, naturally
more resistant animals may accumulate and confound
results. The virus dose required to infect 50 % of the ani-
mals (AID50) is calculated for each experimental group
and statistically compared, often using a form of logistic
regression analysis (described in detail by Spouge and sub-
sequently used or adapted in other studies [21, 26, 27]).
Chenine, et al. used this AID50 study design to model and
demonstrate enhanced susceptibility to SHIV infection
due to systemic helminth coinfection with Schistosoma
mansoni [21]. Chenine, et al. [28] and Ayash-Raskovsky,
et al. [20] first alluded to potential risk enhancement by
reporting that schistosomiasis both reactivates SHIV and
increases viral replication rates. The subsequent suscepti-
bility study in rhesus macaques used intrarectal challenges
with varying doses of a SHIV Clade C infectious molecular
clone [29] (Table 1). The infecting virus dose was 17-fold
lower in S. mansoni-infected animals, compared to con-
trols [21] (p < 0.001, logistic regression methods of Spouge
[26]). The authors described possible mechanisms for in-
creased susceptibility by showing higher concentrations of
viral target cells in S. mansoni-infected macaques and
Fig. 1 Schematic Designs of Enhanced HIV Susceptibility Nonhuman Primate Models. Three potential study designs and analytic approaches for
macaque models of enhanced susceptibility to HIV infection. In panels a and b, the dotted line depicts the experimental arm, subjected to the
susceptibility enhancement factor tested in the study. The solid line depicts the control arm. When increased susceptibility is observed, a left-shift
would occur in the plots along the x-axis. Note that in the absence of observed susceptibility enhancement, the graphical depiction of the
experimental arm would be similar to that of the control arm. a Repeated low-dose exposure infection rates are depicted in Kaplan-Meier survival
curves and analyzed by log-rank testing. Survival, or confirmed macaque infections, are plotted on the y-axis, relative to either the number of virus
exposures or, in our experience with cycling pigtail macaques, menstrual cycles during exposures. b Dose variation models evaluate the probability of
infection (y-axis) relative to decreasing virus dose dilutions (or increasing concentration of challenge virus dose; x-axis). Animal infectious doses required
to infect 50 % of the cohorts (AID50) are determined and analyzed by logistic regression statistical models. (*) Vishwanathan, et al. demonstrated
lubricant-induced cytotoxicity, but not enhancement of SHIV acquisition risk. c Multiple study designs can use categorical measures of infection
probability, such as Fisher’s exact or Chi-square outcome measures to analyze infection rates with and without the proposed enhancement factor
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[21]. To address whether the increased risk was due to
mucosal inflammation and/or subsequent target cell
recruitment, or if systemic effects of schistosomiasis in-
creased SHIV infection risk, a follow-up risk study was
performed again using a virus titration study design, ex-
cept, in this study, macaques were challenged intraven-
ously [30] (Table 1). In this subsequent study, the AID50
and peak virus level between S. mansoni-infected and
control groups were not significantly different, suggest-
ing susceptibility is facilitated by the helminth’s inter-
action at the mucosa, resultant inflammation, and/or
the consequent upregulation of viral replication at the
mucosal surfaces [30].
In an HIV vaccine model using rhesus macaques,
Qureshi, et al. also used a dose escalation model [31]
(Table 1) to determine if a nonhuman primate model
could recapitulate the enhanced susceptibility to HIV in-
fection seen in the human phase III STEP trial [17, 31].
In the trial, preexisting seropositivity to adenovirus sero-
type 5 (Ad5) was associated with increased HIV-1 infec-
tions in men who received an Ad5 HIV vaccine. In the
macaque model, escalating doses of SIVmac251 were
given through repeated penile exposures to animals in-
fected with adenovirus and then vaccinated with an Ad5SIV vaccine [31]. In this model, an enhanced SIV infection
rate was observed in animals with pre-existing Ad5 im-
munity that received low doses (103 TCID 50) of SIV, but
not higher doses. The analytic approaches supporting this
finding included log-rank tests of survival, determin-
ation of relative risks of infection and likelihood-ratios
in statistical models with an assumption of a leaky vac-
cine effect. Moreover, when examining the difference in
the number of infections in the nonhuman primate and
human models, the enhancement was marginal in both,
but of a similar order of magnitude (two in 43 ma-
caques, compared to 16 in approximately 1800 men).
These important findings demonstrate that macaque
models can be used to determine if biomedical preven-
tions increase susceptibility to SIV.
Our group has also employed the use of virus dose ti-
tration challenges to evaluate the effect of rectal lubri-
cants on rectal SHIV acquisition risk [27] (Table 1). This
study was first conceptualized after recent in vitro and
ex vivo studies reported detrimental effects of lubricants
on rectal and genital epithelium [32–34]. The cytotoxicity
phase of the study showed acute effects of a highly hyper-
osmolar lubricant on macaque anorectal tissues [27]. Be-
cause of the overt susceptibility factors (local inflammatory
response, rectal bleeding, epithelial sloughing), a












Virus stock/challenge dose Study design parameters References
Behavioral Factors of Susceptibility Enhancement
Chronic Alcohol Use No Multiple, potential susceptibility factors:
shifts in genital flora, increases in
memory CD4+ T cells (viral targets),
decreases in CD8+ T cells (anti-viral);
↑viremia in treated animals
Male and
Female Rhesus
n/a Designs vary; alcohol steadily
administered via jacketed device
Loganantharaj (2014) [40]a
Poonia (2006; AIDS)a[22]
Poonia ([41]; JAIDS) (2006)a
Rectal Lubricant Use No Acute cytotoxicity observed after
application of tested lubricant, but
no ↑in risk during challenge phase
Male and Female
Cynomologus
SHIVSF162p3 (varying doses) Intrarectal challenge route;
AID50 dose titration model
Vishwanathan (2015) [27]




Yes 2.5-fold ↑ risk in STI-positive animals;
STI-positive animals infected in fewer
menstrual cycles, compared to controls
(p = 0.04, log-rank; p =0.02, Fisher’s exact).
Increases in mucosal pro-inflammatory
cytokines during STI inoculation and
SHIV challenge periods
Female Pigtail SHIVSF162p3 (10 TCID50) Intravaginal challenge route;
repeat low-dose exposures;
exposures per menstrual




Yes Transmission not linked to active
lesions. Possible HSV-2-induced
immunosuppression impairs anti-SHIV
response; subsequent studyb reported
HSV-2 increases concentration of
α4β7high CD4+ T cells (viral targets)
Female Rhesus SHIV-RT (200 and 103
TCID50) ↑Risk with 10
3
Intravaginal challenge route;
animals either treated 1× or
2× with DMPA, then either
200 or 103 TCID50
Crostarosa (2009) [22]
Martinelli [36]b (2011)
Malaria (Systemic Infection) No Evidence of potential susceptibility
factors ;↑ viral load and CCR5+ CD4+
T cells (viral targets) in P. fragile-infected
animals, but risk/hazard ratio
not determined






Yes 17-fold lower dose of virus required
to infect S. mansoni-infected animals;
↑ viremia and replication in CD4+
central memory cells (viral targets)
Female Rhesus SHIV-1157ipd3N4
(Clade C; varying doses)
Intrarectal challenge route;




No Intravenous challenges (compared to
mucosal challenges) did not result in
same increase of SHIV acquisition risk
Female Rhesus SHIV-1157ipd3N4
(Clade C; varying doses)
Intravenous challenge route;
AID50 dose titration model
Siddappa (2011) [30]
Hormonal Factors of Susceptibility Enhancement
Hormone Levels Associated
with Menstrual Cycle Phase
(Endogenous Hormone)
Yesc Exact mechanisms to be determined.
Increased rates of SHIV RNA detection
in late-luteal and menses phases













Table 1 Literature Review of Macaque Models of Enhanced HIV Risk (Continued)
Phase of Menstrual Cycle No Vaginal application of cell-free virus
resulted in infection; 50 % of
macaques infected in luteal phase,
compared to 24 % challenged
in follicular phase
(not statistically significant)
Female Rhesus SIVmac251 (3 × 101 to 3 × 103




different doses of cell-free






Yes 7.7-fold ↑ risk in implanted animals.
DMPA induced significant vaginal
thinning, with ↑peak and 1st
3 months of viremia




Vaccines as a Factor of Susceptibility Enhancement
Ad5d Vaccine (Vaccine-
induced enhancement)
Yes ↑ risk in Ad5 seropositive animals
infected with the lower (103 TCID50)
challenge dose; study recapitulates
lack of Ad5 vaccine efficacy and
model vaccine-induced acquisition
risk enhancement
Male Rhesus SIVmac251 (varying doses) Penile challenge route; 10-fold
increases in virus concentration
(103 to 105); comparisons among
groups +/− Ad5 immunity, SIV
vaccination, and naïve controls
Qureshi (2012) [31]
Relevant literature is grouped by type of susceptibility enhancement factor, with description of study design, parameters, and analytical approach and effect(s) of enhancement factor(s)
Terminology of ‘increased infections in experimental animals over controls’ and ‘increased (↑) risk/susceptibility’ is synonymous with observed enhancement of SIV/SHIV infection susceptibility due to or attributed to
the studied (potential) enhancement factor
aCitations describe studies not reporting or not designed to demonstrate enhanced susceptibility, but describe potential or key susceptibility factors for HIV/SIV/SHIV infection
bFollow-up study to Crostarosa, et al. [22] publication, investigating mechanisms of HSV-2-induced enhanced susceptibility
cAssessed retrospectively, during specific phases of the menstrual cycle
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study design. Despite the acute cytotoxicity, the difference
in SHIVSF162p3 doses required to infect controls versus
lubricant-treated animals was not statistically different.
While this particular study did not report increased risk, it
is prudent to note that despite plausible mechanistic data,
models may not identify increased susceptibility or be suf-
ficiently sensitive to demonstrate modest increases in sus-
ceptibility. Vishwanathan, et al. discussed that possibly the
acute nature or type of induced inflammation was not suf-
ficient to increase infection risk to levels above the 2-fold
theoretical threshold limit with the virus dose-titration
challenge model, or perhaps the highly regenerative nature
of the rectal mucosa negates inflammatory effects of lubri-
cant application [27]. Of note, follow-up studies in rhesus
macaques will use a repeat low-dose design (instead of
AID50) as an alternate model to further evaluate possible
risk enhancement due to rectal lubricant use.
Categorical measures of infection probability
The use of a probability analysis, such chi-square or
Fisher’s exact measures (Fig. 1c) can be applied to a var-
iety of study designs, including repeat low-dose and dose
titration models. This direct comparison considers the
relationship between infection (with the challenge virus)
and the nominal, or categorical, variables of the
presence/absence of the proposed enhancement factor.
Fisher’s exact test is often more appropriate than a chi-
square analysis because of the smaller sample sizes ne-
cessitated in nonhuman primate research. As with the
repeated exposure model, selecting the appropriate virus
dose is also an important factor when designing suscep-
tibility challenge studies with Fisher’s exact analyses. The
use of too high a dose will result in all animals becoming
infected and loss of the ability to observe enhancement
between experimental groups.
While studying the effects of progesterone implants in
macaques, Marx, et. al, provided one of the first descrip-
tions of Depo-Provera’s, or depot medroxyprogesterone
acetate (DMPA), effect on susceptibility to SIV acquisi-
tion and used Fisher’s exact analyses to demonstrate in-
creased SIV risk due to exogenous hormone use [35]
(Table 1). In this study, using an analytical approach
depicted in Fig. 1c, female rhesus macaques received sub-
cutaneous implants of progesterone-containing pellets,
while the control group received placebo implants. After
vaginal challenge with SIVmac251, cell-associated SIV was
detected in 78 % of DMPA-treated animals, but only 10 %
of controls (p < 0.008, Fisher’s exact), 7.7 times the risk [35].
Crostarosa, et al. developed a vaginal herpes simplex
virus type-2 (HSV-2) coinfection model in female rhesus
macaques and used the model to evaluate susceptibility
to vaginal infection with SHIV-RT [22] (Table 1). They
employed a complex study design which also factoredthe role of DMPA on susceptibility, though direct or sta-
tistically significant conclusions were not made on the
effect of the exogenous hormone on susceptibility. Over-
all, using an approach similar to Fig. 1c, conclusions
were drawn from n = 28 macaques and n = 46 macaque
infections/challenges in which macaques remaining
SHIV-RT-negative were reused in subsequent arms.
HSV-2-positive animals which received only one hor-
mone injection showed increased susceptibility to SHIV-
RT infection at 103 TCID50 (100 % infection), relative to
HSV-2-negative controls which also received one Depo-
Provera dose (46 % infection) (p < 0.05, Fisher’s exact)
[22]. This model was then used to elucidate mechanisms
of the enhanced susceptibility, such as increased den-
dritic cell availability as a viral target cell and immuno-
modulation of viral replication [36], and to provide a
more stringent model system for evaluating efficacy of
non-nucleoside reverse transcriptase inhibitor (NNRTI)-
containing microbicides [22, 37] (Table 1).
In our C. trachomatis-T. vaginalis coinfection study,
we corroborated log-rank analyses of enhanced risk with
Fisher’s exact testing [23]. By evaluating the number of
menstrual cycles with and without SHIV infection
among the two experimental groups, STI coinfection
was once again associated with increased risk of vaginal
HIV acquisition (p = 0.02; [23]) (Table 1). This report is
an example of how a multi-statistic approach can be
used to analyze (and potentially strengthen) observations
of enhanced susceptibility.Observations on infection susceptibility from varying
study designs
While the focus of this review has been on research
using nonhuman primate models of HIV susceptibility, it
is still prudent to acknowledge the wealth of other stud-
ies in macaques providing evidence of important and
relevant susceptibility factors, albeit not in the frame-
work of a susceptibility-virus challenge study. For ex-
ample, it has been speculated that HIV susceptibility
varies throughout the menstrual cycle in humans [38],
as demonstrated in macaques challenged with S(H)IV
[24, 25, 39]. Sodora, et al. first described the propensity
for greater rates of infection in the luteal versus follicular
phase of the menstrual cycle in rhesus macaques [39].
Our group addressed the same topic through retrospect-
ive studies in female pigtail macaques by analyzing time
points of first plasma SHIVSF162p3 RNA detection from
repeat low-dose intravaginal challenge studies relative to
the phase of the menstrual cycle [24, 25] (Table 1). The
majority of infections were detected in the follicular
phase, with imputed infection dates (after correcting for
a viral eclipse period) in either the menstrual or pre-
menstrual phases [24, 25]. While these studies were not
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[24, 25, 39], they demonstrate varying and enhanced sus-
ceptibility to S(H)IV infection during certain phases of
the menstrual cycle.
Evidence of susceptibility factors relating to modifiable
behavioral risk factors have also been reported from ma-
caque models of chronic alcohol consumption. Chronic
alcohol usage induces adverse shifts in cellular and mi-
crobial populations in the genital tract, increases
concentrations of viral target cells, gut memory CD4+
T cells, reduces levels of cytolytic T cells, and, in SIV-
infected animals, was associated with higher levels of
viremia [40–42] (Table 1). From human studies, there is
empirical evidence for the likelihood of HIV risk enhance-
ment by other substances, such as cocaine; however, ma-
caque models have not yet been developed to further
investigate this factor [43]. Related to alcohol consump-
tion, further exploration of susceptibility models which
also evaluate the role of gut T regulatory and Th17 cells
would benefit the field. As these and other CD4+ cell pop-
ulations are known to mitigate host response to the virus,
control viral activation and spread, and play a key role in
disease progression, macaque susceptibility enhancement
models incorporating the further study of their role in re-
sistance and susceptibility to infection could prove critical
for HIV prevention efforts [44–47].
In addition to helminth infections, other systemic in-
fections, such as malaria, have been modeled in nonhu-
man primates through which evidence of increased SIV
risk was observed. Rhesus macaques coinfected with
Plasmodium fragile had significantly higher ramp-up
levels of plasma viremia and increased concentrations of
CCR5 +CD4+ T cells (SIV target cells). The study showed
evidence of increased susceptibility but did not specifically
evaluate relative risk or hazard ratios [48] (Table 1). Stud-
ies such as these provide impetus for the development of
additional nonhuman primate susceptibility models and
execution of susceptibility-virus challenge studies designed
to examine the effect of these factors on virus acquisition,
potentially using an approach discussed in this review.
Discussion
This review discusses study design strategies and reported
models of enhanced susceptibility using the framework of
three statistical approaches. The field of nonhuman pri-
mate models for HIV acquisition, pathogenesis, and effi-
cacy testing of prevention methods is comprehensive, with
detailed literature and a great depth of understanding of
how these models can be applied and how the generated
data should be interpreted. In comparison, there is a pau-
city of nonhuman primate models for assessing suscepti-
bility to HIV (using SIV/SHIV) and for evaluating factors
that might increase the risk of virus acquisition. And these
relatively few studies also underscore the difficulty indeveloping efficient (e.g., small animal numbers, stream-
lined design), relevant (e.g., effect size, applicability to the
epidemic), and reliable (e.g., low p values, narrow confi-
dence intervals) nonhuman primate model systems to
examine increased susceptibility. Developing and estab-
lishing such studies may require large numbers of animals,
with multiple study arms to fine-tune study design (for ex-
ample, the Crostarosa, et al. study used a total of 28 ma-
caques [22] and Qureshi, et al. used 43). The studies
described here also provide insight into factors enhancing,
or with the potential to enhance, susceptibility to HIV (or
SIV/SHIV) infection. When designing models of enhanced
susceptibility, one is also faced with the appropriate selec-
tion of relevant factors or a reliable study design approach
to best represent the epidemic. For example, what is the
most relevant genital tract pathogen or form of hormonal
contraception to use? Even the basic question of virus
stock selection can have great bearing on study outcome,
relevance to the epidemic, and the nature of the experi-
mental question(s) [49]. The repeat low-dose model has
been successfully used in efficacy studies [50–54], but per-
haps a virus dose-titration (AID50) model might provide
greater power to detect increases in risk. The ability to an-
ticipate the magnitude of risk from epidemiologic or
in vitro studies could inform model selection. The log-
rank or dose escalation approach may provide greater
power in evaluating acquisition risk in the lower ranges of
magnitude, or modest risk enhancement, whereas Fisher’s
exact testing is perhaps more appropriate in analyzing
higher magnitudes of susceptibility enhancement. It is
possible that the most relevant and robust model system
utilizes a combination of study design approaches de-
scribed herein. For example, Qureshi, et al. elegantly de-
scribed the use of multiple analytical strategies in their
Ad5 vaccine enhancement study [31]. Even when acquisi-
tion risk is anticipated as marginal, it is possible that the
appropriate selection of challenge route, virus titer and
statistical approach can still capture the extent of the risk
enhancement.
We’ve highlighted three possible, and previously de-
scribed [21, 23, 27, 31, 35] study design and statistical
analytical approaches, but readily acknowledge that this
field of research is limited and that future models and
study designs could, and perhaps should, be developed
to better address the question of increased HIV suscepti-
bility. It is possible that a novel system altogether would
be most appropriate for conducting susceptibility stud-
ies. Ideally, a side-by-side comparison of these varying
study design approaches would be conducted, testing
the performance of a factor known to enhance infection
risk (e.g. STIs, DMPA) in each model system. Such an
experiment, albeit resource intensive, would provide a
well-controlled comparison of the various modeling
strategies and statistical analyses.
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susceptibility models are capable of supporting epidemi-
ologic findings of HIV risk, defining susceptibility mech-
anisms or factors, and identifying targets for focused
interventions. Moreover, models of enhanced susceptibil-
ity provide a system with which biomedical preventions
can be rigorously tested in the context of “real-world” sus-
ceptibility conditions, prior to proceeding to complex and
costly human clinical trials. As previously mentioned, the
use of an increased risk model to test candidate clinical
trial prevention strategies could alert us to possible sus-
ceptibility enhancement, prior to the introduction in
humans. One could argue the paucity of such models is a
hindrance to the advancement of broadly efficacious
HIV prevention strategies. The field of HIV prevention
research still doesn’t have the “perfect” model of HIV
acquisition, a goal that may indeed be unattainable.
Nonetheless, efforts to refine our models may necessi-
tate a combination of varying study designs for differing
genders, infection routes and cofactors. Continued work
in the development and use of nonhuman primate
models of enhanced susceptibility could, or would, in-
crease our understanding of acquisition and provide
better models for prevention testing.
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